This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-09-0049v1 69/15/6179    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Liao, H.-J. Articles by Carpenter, G. PubMed PubMed Citation Articles by Liao, H.-J. Articles by Carpenter, G.

Cetuximab/C225-Induced Intracellular Trafficking of Epidermal Growth Factor Receptor

Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tenessee

Requests for reprints: Graham Carpenter, Vanderbilt University School of Medicine, 21st Avenue South, Nashville, TN 37232-0146. Phone: 615-322-6678; Fax: 615-322-2931; E-mail: graham.carpenter{at}vanderbilt.edu.

Key Words: C225 • EGF receptor • Sec61

The monoclonal antibody C225 interacts with the ectodomain of the epidermal growth factor (EGF) receptor (EGFR) to block ligand binding and initiates receptor endocytosis and intracellular trafficking. The data herein show that C225-dependent EGFR trafficking relocalizes the receptor to the endoplasmic reticulum (ER) and nucleus. This mechanism, which also involves interaction of the C225-internalized receptor with the Sec61 translocon within the ER, is, in most respects, analogous to the pathway previously described for EGF-induced trafficking to the ER and nucleus. However, although inhibition of receptor tyrosine kinase activity blocks EGF-induced nuclear localization of the receptor, the same kinase inhibitors stimulate C225-dependent nuclear localization of EGFR in the nucleus. In contrast, the kinase inhibitor Lapatinib fails to stimulate nuclear accumulation of the receptor in C225-treated cells and does not provoke receptor dimerization as do inhibitors that recognize the open conformation of the receptor kinase. This suggests that inhibitor-dependent receptor dimerization may facilitate C225-induced receptor trafficking. [Cancer Res 2009;69(15):6179–83]